Physician profile
Gary M Onady
NPI 1396792347
$786.92
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $362 · 2021: $53.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $261.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $177.27 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $65.78 | 2019 | |
| Amgen INC. | $64.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.78 | 2019 | |
| Radius Health, INC. | $28.10 | 2019-2020 | |
| Novo Nordisk INC | $26.96 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.85 | 2019 | |
| Romark Laboratories, Lc | $20.76 | 2019 | |
| Sanofi Pasteur INC. | $17.45 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.78 | 2021 | |
| Allergan, INC. | $12.31 | 2020 | |
| Lilly USA, LLC | $11.36 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Onady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.